10-K: CytoSorbents Reports 2024 Results, Awaits Key Regulatory Decisions for DrugSorb-ATR

CytoSorbents Corporation files its 2024 10-K, highlighting revenue growth, reduced operating losses, and progress towards regulatory approval for DrugSorb-ATR.

Summary

• CytoSorbents Corporation has filed its Annual Report on Form 10-K for the year ended December 31, 2024, which includes restated sections of the 2023 consolidated financial statements to correct misstatements related to inventory and stock-based compensation expense for restricted stock units.
• The company is awaiting regulatory decisions from the FDA and Health Canada regarding its DrugSorb-ATR antithrombotic removal system, expected in 2025.
• Total product revenue for 2024 was $35.6 million, a 15% increase compared to 2023.
• Gross profit for 2024 was $25.1 million, a 14% increase compared to 2023.
• The loss from operations improved by 47% to approximately $16.8 million in 2024.
• The company secured a $20 million credit facility and launched the PuriFi Pump.
• A De Novo marketing application for DrugSorb-ATR was submitted to the FDA in September 2024 and accepted for substantive review in October 2024.
• The company received Medical Device Single Audit Program (MDSAP) certification in November 2024 and submitted its Medical Device License (MDL) application to Health Canada.
• Over 270,000 CytoSorb treatments have been delivered cumulatively to date.
• In January 2025, the company completed a shareholder Rights Offering, raising $6.25 million, and an additional $1.6 million was raised with the exercise of Series A Right Warrants in February 2025.
• The equity raises also provided for $5 million of restricted cash to become unrestricted, increasing unrestricted cash liquidity by a total of $12.3 million.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is revenue growth and reduced operating losses, the company still faces significant financial challenges, including an accumulated deficit and the need for additional capital. The regulatory uncertainty surrounding DrugSorb-ATR also contributes to a neutral outlook.

Positives

• Product revenue increased by 15% to $35.6 million.
• Gross profit increased by 14% to $25.1 million.
• Operating loss decreased by 47% to $16.8 million.
• The company secured a $20 million credit facility.
• The company completed a shareholder Rights Offering in January 2025, raising $6.25 million, and an additional $1.6 million was raised with the exercise of Series A Right Warrants in February 2025.
• The equity raises also provided for $5 million of restricted cash to become unrestricted, increasing unrestricted cash liquidity by a total of $12.3 million.

Negatives

• The company has a history of losses and an accumulated deficit of approximately $304.0 million as of December 31, 2024.
• The company will require additional capital in the future to fund its operations.
• The company identified a material weakness in its internal control over financial reporting.

Risks

• The company's ability to achieve profitability depends on continued adoption of its products, regulatory approvals, and sufficient funding.
• A pandemic, epidemic, or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect the company's business and operations.
• The company's operating results are subject to seasonal fluctuation.
• Acceptance of the company's medical devices in the marketplace is uncertain.
• The company may face litigation from third parties claiming that its products infringe on their intellectual property rights, or seek to challenge the validity of the company's patents.
• The company has limited manufacturing experience and capabilities, and may not be able to manufacture sufficient quantities at an acceptable cost or quality, or without shut-downs or delays.
• The company could be adversely affected by violations of the Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.
• Cyberattacks and other security breaches could compromise the company's proprietary and confidential information which could harm the company's business and reputation.
• The price of the company's common stock has been highly volatile due to factors that will continue to affect the price of the company's stock.
• The evaluation of potential financial misstatements and determination of the materiality and need to restate certain sections of our previously issued consolidated financial statements has been time consuming, resulted in additional expense and may subject us to additional risks and uncertainties, including loss of investor confidence, and the increased possibility of litigation and regulatory inquiries.

Future Outlook

The company anticipates regulatory decisions from the FDA and Health Canada regarding DrugSorb-ATR in 2025 and expects to rapidly commercialize the product upon approval.

Industry Context

The company operates in the blood purification market, focusing on critical care and cardiac surgery applications. It faces competition from other companies offering blood purification technologies and pharmaceutical interventions.

Comparison to Industry Standards

• CytoSorbents competes with companies like Baxter/Vantiv, Toray, Jafron, Efferon, and Fresenius Medical Care in the blood purification market.
• DrugSorb-ATR competes with PhaseBio's bentracimab (now owned by SFJ Pharmaceuticals and licensed to SERB Pharmaceuticals) for blood thinner reversal, but CytoSorbents believes DrugSorb-ATR has advantages in safety, cost, and ease of use.
• ECOS-300CY competes with Aferetica srl in the ex vivo organ perfusion market.
• VetResQ competes with Aimalojic in the U.S. animal health market.

Management Changes

Corporate Governance

Legal Proceedings

• A former employee filed a complaint against the company alleging breach of the New Jersey Conscientious Employee Protection Act (CEPA).

Stakeholder Impact

• Shareholders: Dilution may occur from future equity offerings.
• Employees: Potential for job losses if the company needs to reduce headcount.
• Customers: Access to innovative blood purification technologies.
• Suppliers: Continued business relationships.
• Creditors: Repayment of debt obligations.

Next Steps

• The company is awaiting regulatory decisions from the FDA and Health Canada regarding DrugSorb-ATR in 2025.
• The company plans to pursue CMS TCET coverage for DrugSorb-ATR.
• The company will continue to evaluate various financing alternatives.

Key Dates

Keywords

DrugSorb-ATR, CytoSorb, blood purification, regulatory approval, financial results, 10-K, CytoSorbents